In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Novo Nordisk ’s oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about ...

Eli Lilly, the maker of Zepbound and Mounjaro, said it's experimental GLP-1 pill successfully helped adults with obesity lose ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

A daily pill that works like Ozempic can help slimmers lose an average of two stone, trials have found. The study of ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially ...

US stocks were mixed Thursday morning as President Trump's sweeping tariffs hit dozens of US trade partners after his ...

Eli Lilly's stock crashed over 14% despite strong Q2 earnings, as disappointing weight-loss pill trial results overshadowed 38% revenue growth and raised guidance.

By taking 36 mg once per day - without food and water restrictions - participants lost an average of 12.4 percent of their body weight - about 27.3 pounds (12.4 kilograms). This was over the span of ...

Aug 7 - Eli Lilly posted blockbuster Q2 results but saw its stock slide about 7% on mixed Q2 Earnings news. The ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...